Alzamend Non Operating Income Net Other from 2010 to 2026

ALZN Stock  USD 1.65  0.02  1.23%   
Alzamend Neuro Non Operating Income Net Other yearly trend continues to be very stable with very little volatility. Non Operating Income Net Other is likely to drop to 3,420. During the period from 2010 to 2026, Alzamend Neuro Non Operating Income Net Other quarterly data regression pattern had sample variance of 832.7 M and median of  62,418. View All Fundamentals
 
Non Operating Income Net Other  
First Reported
2010-12-31
Previous Quarter
3.6 K
Current Value
3.4 K
Quarterly Volatility
28.9 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Alzamend Neuro financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alzamend Neuro's main balance sheet or income statement drivers, such as Depreciation And Amortization of 43.4 K, Selling General Administrative of 3.3 M or Other Operating Expenses of 6.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.65. Alzamend financial statements analysis is a perfect complement when working with Alzamend Neuro Valuation or Volatility modules.
  
Build AI portfolio with Alzamend Stock
Check out the analysis of Alzamend Neuro Correlation against competitors.
To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.
Evaluating Alzamend Neuro's Non Operating Income Net Other across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Alzamend Neuro's fundamental strength.

Latest Alzamend Neuro's Non Operating Income Net Other Growth Pattern

Below is the plot of the Non Operating Income Net Other of Alzamend Neuro over the last few years. It is Alzamend Neuro's Non Operating Income Net Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alzamend Neuro's overall financial position and show how it may be relating to other accounts over time.
Non Operating Income Net Other10 Years Trend
Slightly volatile
   Non Operating Income Net Other   
       Timeline  

Alzamend Non Operating Income Net Other Regression Statistics

Arithmetic Mean41,742
Geometric Mean23,306
Coefficient Of Variation69.13
Mean Deviation26,757
Median62,418
Standard Deviation28,857
Sample Variance832.7M
Range59K
R-Value(0.83)
Mean Square Error276.3M
R-Squared0.69
Significance0.000037
Slope(4,743)
Total Sum of Squares13.3B

Alzamend Non Operating Income Net Other History

2026 3420.0
2025 3600.0
2021 4000.0

About Alzamend Neuro Financial Statements

Alzamend Neuro investors utilize fundamental indicators, such as Non Operating Income Net Other, to predict how Alzamend Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Non Operating Income Net Other3.6 K3.4 K

Pair Trading with Alzamend Neuro

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alzamend Neuro position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alzamend Neuro will appreciate offsetting losses from the drop in the long position's value.

Moving against Alzamend Stock

  0.61EQ EquilliumPairCorr
  0.42PYC Physiomics PlcPairCorr
  0.39DSGN Design TherapeuticsPairCorr
The ability to find closely correlated positions to Alzamend Neuro could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alzamend Neuro when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alzamend Neuro - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alzamend Neuro to buy it.
The correlation of Alzamend Neuro is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alzamend Neuro moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alzamend Neuro moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alzamend Neuro can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Alzamend Neuro offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alzamend Neuro's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alzamend Neuro Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alzamend Neuro Stock:
Check out the analysis of Alzamend Neuro Correlation against competitors.
To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Will Biotechnology sector continue expanding? Could Alzamend diversify its offerings? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Alzamend Neuro data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(2.67)
Return On Assets
(0.73)
Return On Equity
(1.45)
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Alzamend Neuro's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Alzamend Neuro represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Alzamend Neuro's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.